Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.66 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.66 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.66 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | PLD2 | O14939 | 4/20 | 0.49 |
| ▸ | PLD1 | Q13393 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996959 | 1.00 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL2996956 | 1.00 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL3002989 | 0.92 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4636114 | 0.92 | CHRM1 (0.67) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL2998801 | 0.90 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL2998817 | 0.90 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL2998805 | 0.90 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13243471 | 0.89 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13243479 | 0.88 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL13243474 | 0.88 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | claimed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173935-A1 | Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia | CHRM1, CHRM2, CHRM5 | CHRM1 1/4885CHRM2 2/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.